HEAD AND NECK SQUAMOUS CELL CARCINOMA HNSCC
Clinical trials for HEAD AND NECK SQUAMOUS CELL CARCINOMA HNSCC explained in plain language.
Never miss a new study
Get alerted when new HEAD AND NECK SQUAMOUS CELL CARCINOMA HNSCC trials appear
Sign up with your email to follow new studies for HEAD AND NECK SQUAMOUS CELL CARCINOMA HNSCC, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Radioactive drug trial for advanced cancers halted early
Disease control TerminatedThis study tested a new radioactive drug, [225Ac]-FPI-1434, in people with advanced solid tumors that had stopped responding to standard treatments. The goal was to check safety and find the right dose. The study was terminated early, so results are limited. It involved 78 partic…
Matched conditions: HEAD AND NECK SQUAMOUS CELL CARCINOMA HNSCC
Phase: PHASE1 • Sponsor: Fusion Pharmaceuticals Inc. • Aim: Disease control
Last updated May 17, 2026 06:47 UTC
-
Experimental cancer drug trial halted early
Disease control TerminatedThis study tested an experimental drug called TransCon TLR7/8 Agonist, given as an injection into tumors, either alone or with another drug (pembrolizumab). It aimed to find a safe dose and check for side effects in people with advanced solid tumors that had stopped responding to…
Matched conditions: HEAD AND NECK SQUAMOUS CELL CARCINOMA HNSCC
Phase: PHASE1, PHASE2 • Sponsor: Ascendis Pharma Oncology Division A/S • Aim: Disease control
Last updated May 12, 2026 13:43 UTC